Verteporfin worth it for age-related macular degeneration in the UK?

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1345, 2002-01, pp. : 7-7

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Off-Label Use of Bevacizumab for the Treatment of Age-Related Macular Degeneration: What is the Evidence?

By Ziemssen Focke

Drugs & Aging, Vol. 26, Iss. 4, 2009-05 ,pp. : 295-320

Adis International

Access to resources Recommend Favorite

Therapeutic Efficacy of Bevacizumab for Age-Related Macular Degeneration: What are the Implications of CATT for Routine Management?

By Ziemssen Focke Sobolewska Bianka

Drugs & Aging, Vol. 28, Iss. 11, 2011-11 ,pp. : 853-865

Adis International

Access to resources Recommend Favorite

A Preliminary Benefit-Risk Assessment of Verteporfin in Age-Related Macular Degeneration

By Wickens Jason Blinder Kevin J.

Drug Safety, Vol. 29, Iss. 3, 2006-01 ,pp. : 189-199

Adis International

Access to resources Recommend Favorite

Which anaesthetic worth it for day surgery in the UK?

Inpharma, Vol. 1, Iss. 1391, 2003-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Safety of verteporfin for treatment of subfoveal choroidal neovascular membranes associated with age-related macular degeneration

By Gaynes Bruce I Fiscella Richard G

Expert Opinion on Drug Safety, Vol. 3, Iss. 4, 2004-07 ,pp. : 345-361

Informa Healthcare

Access to resources Recommend Favorite